First Name	Last Name	Degree(s)	Affiliation	Country	Specialty Area	Activities	Specialties	Group to Mentor
Vikram	Arya	PhD	Government/Regulatory	US	Dr. Vikram Arya earned his Ph.D. in Pharmaceutics from the University of Florida. He has published articles on drug-drug interactions and impact of transporter modulation on drug disposition and has presented at various conferences. He is a Fellow of the American College of Clinical Pharmacology (ACCP) and currently serves as President-Elect of ACCP. He holds an Adjunct Clinical Professor appointment in the Department of Pharmacy Practice at Mercer University, Atlanta, GA, Adjunct Assistant Professor appointment in the Department of Pharmaceutical Sciences at the University of Tennessee, Adjunct Associate Professor appointment in the Department of Pharmaceutics, University of Florida, and Adjunct Professor appointment in the Department of Pharmacotherapy in the University of North Texas System College of Pharmacy. He serves on the Editorial Board of the Journal of Clinical Pharmacology (JCP) and International Journal of Clinical Pharmacology and Therapeutics (IJCPT).	Regulatory	Infectious Disease	Early-stage Professionals Industry/Regulatory Track
Kacey	Anderson	PhD	Industry	US	Dr. Anderson is a clinical pharmacologist working in the pharmaceutical industry. She has comprehensive clinical pharmacology experience from Phase 1 to Phase 3 and has been the clinical pharmacology lead on several project teams for inflammation small molecules. She has experience in authoring multiple regulatory submissions, included IND/CTA submissions and NDA/MAA/PMDA submissions.	Clinical, Research	PK/PD/DM, Drug Interactions	Students & Trainees (undergrad, graduate, post-doc); Early-stage Professionals Industry/Regulatory Track
Mohamed	Badawi	PhD	Industry	US	Dr. Badawi received his PhD from the Ohio State University and currently works as an Associate Director at AbbVie Inc serving as the clinical pharmacology lead for several oncology early assets including small molecules, monoclonal antibodies and antibody drug conjugates.	Research, Administration/Management, Teaching	Cancer Therapies, Drug Interactions, Special Populations	Students & Trainees (undergrad, graduate, post-doc); Early-stage Professionals Industry/Regulatory Track
Sihem	Bihorel	MS, PharmD, PhD	Industry	US	Dr. Sihem Bihorel (née Ait-Oudhia) is a Senior Director at Merck & Co. She holds two Master's degrees in Immunology and Pharmacometrics, a PharmD degree, and a PhD degree from the University Paris Descartes in France. Dr. Bihorel conducted her PhD research in the Department of Pharmaceutical Sciences at SUNY at Buffalo, where she later served as a Postdoctoral Associate and Research Assistant Professor. Prior to joining Merck & Co., Dr. Bihorel was an Assistant Professor at the Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida. Dr. Bihorel is an expert in the end-to-end application of model-informed drug development using various quantitative modeling and simulation approaches across multiple therapeutic areas such as oncology, hematology, immunology, cardio-metabolic diseases, infectious diseases, and drug delivery. She has authored numerous scientific publications in international peer-reviewed journals, book chapters, and presented her work as posters, talks, and webinars at various international conferences. Dr. Bihorel serves on the Editorial Board of the Journal of Pharmacokinetics and Pharmacodynamics and Clinical Pharmacology and Therapeutics. She is also a mentor to many students, postdocs, scholars, and scientists in academia and the pharmaceutical industry.	Research, Teaching	PK/PD/DM, Cancer Therapies, Translational Medicine	Students & Trainees (undergrad, graduate, post-doc) as well as Early-stage Professionals Academic Track as well as Industry Track
Christine	Brandquist	PharmD	Industry	US	Dr. Brandquist a clinical pharmacokineticist with a focus on pharmacokinetic and pharmacodynamic assessments in Phase 1 clinical trials. She is involved in study design development and submission-ready protocol writing, data analysis, and report writing. The types of Phase 1 studies that she typically works on are First-in-Human Single and Multiple Ascending Doses, Bioavailability, Bioequivalence, Food Effect, Drug-Drug Interactions, Renal Impairment, Hepatic Impairment, and Gender/Ethnicity studies. In addition, she has experience in population pharmacokinetics/pharmacometrics. Dr. Brandquist is a long-time Member of ACCP and has served in many roles, including as the Chair of the Membership Committee, and has mentored many young colleagues.	Clinical, Consultant	PK/PD/DM, Biostatistics/Clinical Trials, Pharmacometrics	Students & Trainees (undergrad, graduate, post-doc); Early-stage Professionals Industry/Regulatory Track
Matthew	Dufek	PhD	Industry	US	Dr. Dufek is Director of Clinical pharmacology at Abbvie in the department of clinical pharmacology and pharmacometrics (since 2013). IHe is the lead clinical pharmacology representative on the global development teams within the General Medicine Therapeutic Area. Some of the compounds he currently supports are in the therapeutic areas of cystic fibrosis, oncology, anti-infective (HIV and HCV), men's & women's health (endometriosis and fibroids), renal disease, pediatric and mature products. The majority of his responsibilities are leading the development of and strategic planning of clinical development plans for the execution of Phase 1-3 clinical studies within these project teams and review of proposals with executive management and governance committees. Other responsibilities have included, serving as clinical pharmacology team lead and steering committee member for external collaborations between AbbVie and other pharmaceutical development companies (US and Global) and external asset review and due diligences.	Clinical, Administration/Management	PK/PD/DM, Clinical Research, Drug Interactions	Students & Trainees (PhD and post-doc); Early-stage Professionals Industry Track
Mike	Fossler	PharmD, PhD, FCP	Industry	US	Michael J. Fossler is Vice-President, Clinical Development and Quantitative Sciences, at Trevena, Inc. From 1995 to 2000, Dr. Fossler was employed by the FDA as a clinical pharmacology reviewer in the Division of Metabolic and Endocrine Drug Products. In 1998, he was promoted to Senior Reviewer, and joined the Pharmacometrics group at FDA, where he was responsible for reviewing and performing population PK/PD analyses. He left the Agency in 2000 and joined the Clinical Pharmacokinetics Group at DuPont Pharmaceuticals, where he had major responsibility for PK/PD analyses in the cardiovascular and anti-inflammatory areas. In November, 2001, he joined GlaxoSmithKline, where he continued to work in the cardiovascular area, and eventually headed a group of nine pharmacometrics scientists. He left GSK in 2015 to assume his present role at Trevena, Inc., where he heads up clinical pharmacology, clinical operations, biostatistics, programming and data management. He received a Pharm. D. (1992) and Ph. D. (1995) degrees from the University of Maryland. Dr. Fossler is a Fellow of the American Foundation for Pharmaceutical Education, a Fellow of the American College of Clinical Pharmacology, a past President of the College and is an Honorary Regent. He holds adjunct faculty appointments at the University of Maryland School of Pharmacy, Mercer University, and the University of North Texas, and is on the faculty of the University of California's American Course on Drug Development and Regulatory Science.	Administration/Management, Research	PK/PD/DM, Pharmacometrics	Students & Trainees (PhD and post-doc); Early-Stage Professionals Industry Track

Tushar	Garimella	PhD	Industry	US	Dr. Garimella is an industry professional with more than 12 years of experience in Clinical Pharmacology and Pharmacometrics in multiple therapeutic areas. Currently employed in Bristol-Myers Squibb as therapeutic area head for Clinical Pharmacology for Cardiovascular assets, Tushar has experience across all phases of drug development. Previous experience includes hepatitis C, neuroscience and CKD and extensive experience in model informed drug development and regulatory interactions with multiple agencies including FDA, EMA, PMDA, KFDA, CDE and TFDA.	Clinical	Clinical Research, Translational Medicine	Students & Trainees (undergrad, graduate, post-doc); Early-Stage Professionals Industry/Regulatory Track
Suzette	Girgis	PhD	Industry	US	Dr. Girgis received her PhD from the University of Rhode Island. She has strong drug development experience (more than 20 years) in small molecule, cell therapy and biologics (including bispecifics such as BCMA and GPRC5D) at early and late stage of development, including filing and registration across different therapeutic areas with emphasis on oncology. Her skills include - expert in selecting the dose regimen for First in Human and the Proof of Concept studies, - solid clinical experience in study execution and data interpretation, - strong managerial and mentoring experience - influential leadership skills - oversee the clinical pharmacology strategy of heme compounds - significant contributions to various compounds submissions (such as teclistamab, Velcade, Dacogen, Nulojix) - Due Diligence activities - business and operation strategy.	Research	Pharmacokinetics/Pharmacodynamics/Drug Metaboliam, Pharmacometrics, Cancer Therpaies	Students & Trainees; Early-Stage Professionals Industry Track
Navin	Goyal	PhD	Industry	US	Dr. Goyal has 8 years of experience in Clinical Pharmacology and Pharmacometrics working in Industry (GlaxoSmithKline) in different therapy areas. He is happy to share experience and mentor trainees/young professionals of what skills they need to sharpen, what should they expect when joining the industry at entry level positions.	Research, Clinical	PK/PD/DM, Pharmacometrics, Translational Medicine	Students & Trainees; Early-Stage Professionals Industry/Regulatory
Neeraj	Gupta	PhD	Industry	US	Dr. Gupta is an expert in clinical pharmacology and pharmacometrics and has extensive experience as a drug developer in oncology drug development. He holds a PhD degree in Pharmaceutics from the Univ of Iowa with specialization in pharmacokinetic/pharmacodynamic sciences. He has held positions in the pharmaceutical industry at Abbott and Millennium/Takeda. Currently at Takeda, Dr. Gupta leads a group of PhD-level clinical pharmacologists responsible for representing the discipline on drug development program teams from translational research through late-stage clinical development. He directly serves as the Global Clinical Pharmacology Leader for two of Takeda Oncology's marketed products, the proteasome inhibitor ixazomib for multiple myeloma and the ALK inhibitor brigatinib for ALK+ Non-small cell lung cancer, where his superior scientific and strategic leadership have been central to the development of these drugs. Dr. Gupta has published over 40 peer-reviewed papers in prestigious journals and over 90 abstracts/conference presentations at national and international meetings serving the communities of clinical pharmacology, translational medicine, cancer research, oncology clinical medicine and drug development/regulatory science. He has served as an invited speaker/faculty member or session chair at multiple major national and international meetings and at the FDA on topics ranging from model-informed drug development, proarrhythmic risk assessment in drug development and clinical pharmacology/pharmacometrics in oncology drug development.	Research, Clinical	Pharmacometrics, Cancer Therapies, Regulatory/Scientific Affairs	Students & Trainees, Early-Stage Professions, Industry/Regulatory Track
Matthew	Hruska	PharmD, PhD	Industry	US		Clinical, Research	PK/PD/DM, Drug Interactions,	Early Stage Professionals & Students and
Manoj	Jadhav	PhD	Industry	US	Dr. Jadhav is a PhD in Pharmaceutical Technology and a trained clinical pharmacologist. He has worked on both non-clinical and clinical drug development programs in infectious diseases and cardiovascular diseases both in India and USA. He has published over 25 research papers in peer reviewed journals and has worked at both industry and academia.	Administration/Management, Research	Drug Discovery/Formulations	Students & Trainees, Early-Stage Professionals, Industry/Regulatory Track
Ahmed	Nader	PhD	Industry	US	Dr. Nader is the Assoc Director of Clinical Pharmacology Modeling & Simulation at GlaxoSmithKline	Research, Other	Pharmacometrics, PK/PD/DM, Immunology/Rheumatology	Students & Trainees, Early-Stage Professionals (Industry/Regulatory) track
Ahmed	Salem	PhD	Industry	US	Dr. Ahmed Salem is an associate director of Clinical Pharmacology and Pharmacometrics at AbbVie, North Chicago, USA, where he leads a group of clinical pharmacologists supporting the development of targeted anti-cancer agents. Dr. Salem is a pharmacist and holds a PhD in Clinical Pharmacology from University of Minnesota with minor in Biostatistics. Dr. Salem's research at University of Minnesota focused on pharmacometric analyses of anti-HIV and anti-MRSA agents. In the industry, Dr. Salem has supported the clinical development of small and large molecules in the oncology, virology and women's health therapeutic areas. Dr. Salem has contributed to the approval of several new and supplemental drug applications and marketing authorization applications. His most recent accomplishment was leading the clinical pharmacology strategy for the first-in-class BCL-2 inhibitor; venetoclax, contributing to its approval in the US and EU. Dr. Salem has published over 80 peer-reviewed publications including 33 original research articles. Dr. Salem serves on the STYP Committee of the American College of Clinical Pharmacology (ACCP) and on the publications committee of the International Society of Pharmacometrics (ISoP). He is also a peer review for numerous clinical pharmacology journals and is a member of the Rho Chi pharmacy Phi Kappa Phi Honor societies.	Clinical, Research	PK/PD/DM, Infectious Disease, Pharmacometrics	Early-Stage Professionals/Industry Track

Mohamadi	Sarkar	MPharm, PhD, FCCP	Industry	US	Dr. Sarkar is a Fellow of Scientific Strategy at Altria Client Services LLC, and is an Affiliate Professor of Clinical Pharmacology at the Medical College of Virginia at VCU. He provides strategic direction towards developing the science and evidence for regulatory submissions for non-combustible tobacco products for Altria's tobacco operating companies. He has authored more than 100 scientific peer-reviewed publications and presentations at scientific meetings. Dr. Sarkar has also participated in multiple seminar presentations and authored a variety of scientific book chapters related to his areas of expertise.	Clinical, Regulatory	Biomarkers/Precision Medicine, Biostatistics/Clinical Trials, Clinical Research	All levels, Looking for a long term mentoring relationship
Aarti	Sawant Basak	PhD	Industry	US	Dr. Sawant is an industry expert with experience in clinical pharmacology. She has extensive experience in end-to-end drug development with 17 years spanning across different therapeutic areas including oncology, neuroscience, immunology, and cardiovascular and metabolic disorders. Dr. Sawant received her PhD in University of Illinois (UIC) College of Pharmacy, UIC NIH Botanical center evaluating hepatotoxicity of natural products and dietary supplement. After completing her Ph.D in Dec 2006, Dr. Sawant spent 15+ years at Pfizer initially in the drug metabolism and pharmacodynamics group and later on in Clinical Pharmacology. Currently at AstraZeneca, Dr. Sawant supports oncology programs across different modalities from candidate nomination through life cycle management, including approved products (e.g.Tagrisso). In this role as a global clinical pharmacology lead, she drives dose optimization strategies in drug development. She also serves as an adjunct faculty at the University of Arizona R.K. Coit College of Pharmacy and mentors students and staff within and through societies externally (e.g. ASCPT and HBA). She is a reviewer for journals within the community and serves as an editorial board member at DMD since 2018. She has published peer-reviewed articles in clinical pharmacology, modeling and simulation, drug interactions, combination, translational pharmacology, PK/PD, and PBPK.	Clinical, Research, Regulatory	PK/PD/DM, Special Populations, Clinical Research	Students & Trainees, Early-Stage Professionals Industry Track
Mohamadi	Shebley	PhD	Industry	US	Dr. Shebley received his PhD in Pharmacology from the Univ of Michigan, with focus on drug-drug interaction. He joined industry after graduation and worked across divisions of drug discovery and development, spanning DMPK, translational science, modeling and simulation, and clinical pharmacology and pharmacometrics. He is currently serving as Clinical Pharmacology Group Leader supporting PhD/PharmD clinical pharmacologists working across development projects ranging from FIH to commercialization in the Specialty therapeutic area (general medicine/infectious disease), with previous experience in oncology. He became a Fellow of Clinical Pharmacology in ACCP in 2019 and serves on the ACCP Membership Committee and ACCP 2022 Annual Meeting Programming Committee.	Research, Clinical	PK/PD/DM, Drug Interactions, Pharmacometrics	Students & Trainees, Early-Stage Professionals (Industry/Regulatory) track
Suneet	Shukla	PhD	Industry	US	Dr Suneet Shukla is a pharmacist by educational training with a PhD in molecular pharmacology, studying drug transporters, and their role in fungal infections, cancer drug resistance, and altering ADME-toxicity of drugs. He worked at the US Food and Drug Administration in the Offices of New Drug Products, Generic Drugs and Clinical Pharmacology and served as reviewer and acting team lead where his responsibilities included the review of INDs, NDAs, ANDAs, and other regulatory submissions from a biopharmaceutics, bioequivalence and clinical pharmacology perspectives. He has published several highly cited research and review articles, received patents, awards from NIH and FDA. He has served on panels evaluating research grants submitted to NIH and FDA, mentored several undergraduate, graduate and post-doctoral trainees and has served as the lead instructor of the medical pharmacology course at the Foundation for Advanced Education in the Sciences (FAES) Graduate School, NIH. He is currently working as Director (Clinical Pharmacology) at Boehringer Ingelheim Pharmaceuticals, USA.	Regulatory	PK/PD/DM, Pharmacometrics	Students & Trainees, Early-Stage Professionals, Industry/Regulatory Track
Kannan	Sridharan	MBBS, MD, DM	Academia	Bahrain	Dr. Sridharan received his MBBS from Madurai Medical College, his MD in Pharmacology from Madurai Medical College and Hospital and his DM in Clinical Pharmacology from Maharashtra University of Health Sciences. He is a clinical pharmacologist with extensive experience in teaching pharmacology/therapeutics, carrying out research in the fields of pharmacokinetics, pharmacogenetics, evidence-based medicine, systematic reviews, and meta-analysis.	Research, Teaching	Clinical Research, Pharmacogenomics, Pharmacokinetics/Pharmacodymanics/Drug Metabolism	Students & Trainees, PharmD/grad students, Academic Track
Meenakshi	Srinivasan	PharmD	Industry	US	Meenakshi Srinivasan received her PharmD from Manipal University, India and subsequently received training in clinical pharmacometrics and pharmacoeconomics as a postdoctoral research associate at the University of North Texas health Science Center at Fort Worth, TX. Following this, she was a University of Florida-GlaxoSmithKline postdoctoral fellow in pharmacokinetics/pharmacodynamics and gained experience in antibiotic drug development. Currently, she works in the Clinical Pharmacology, Modeling and Simulation (CPMS) team at GSK, Collegeville, PA supporting oncology drug development. She is determined and excited to mentor students and trainees who wish to pursue a career in clinical pharmacology in the pharmaceutical industry.	Research	Pharmacometrics, Outcomes Research/Pharmacoepidemiology, Biostatistics/Clinical Trials	Students & Trainees, PharmD/grad students, Industry Track